

CONTACT:

Steve Hanley MediBeacon Inc.

Office - 314-269-5808 Email: Hanley@medibeacon.com

www.medibeacon.com

**NEWS UPDATE** 

## **MediBeacon Presents Gastrointestinal Permeability Research**

## Fluorescent Detection Technology for Use in Gastroenterology

**CHICAGO, May 6, 2017** – Dr. Richard B. Dorshow, Ph.D., Chief Scientific Officer of MediBeacon and Phillip I. Tarr MD, Director of the Division of Pediatric Gastroenterology, Hepatology and Nutrition at the Washington University School of Medicine and St. Louis Children's Hospital presented the results of initial research focused on the measurement of gut permeability using MediBeacon fluorescent tracer agent technology at Digestive Disease Week 2017. The work was funded by a Phase I Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation to Washington University.

Together, Tarr and MediBeacon continue to pursue this innovative global health and development

research project for monitoring human gut permeability under a Phase II Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation that was announced in October 2016.

Digestive Disease Week® (DDW) is the world's leading educational forum for academicians, clinicians, researchers, students and trainees working in gastroenterology, hepatology, GI endoscopy, gastrointestinal surgery and related fields. The conference draws approximately 15,000 attendees from across the globe.



The poster entitled "Measurement of gut permeability using fluorescent tracer agent technology" is available for viewing or downloads at MediBeacon.com.

###

## About MediBeacon Inc.

MediBeacon's mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property estate. MediBeacon's portfolio includes a renal function system that uses an optical skin sensor combined with a proprietary fluorescent tracer agent that glows in the presence of light. This system, currently in human studies, is designed to provide clinicians continuous real-time monitoring of a patient's kidney function.

Learn more about MediBeacon at www.medibeacon.com